XM does not provide services to residents of the United States of America.
G
G

Grifols

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Grifols' Board Approves Resignation Of Tomás Dagá Gelabert To His Office As Secretary Non-Member Of Audit Committee

BRIEF-Grifols' Board Approves Resignation Of Tomás Dagá Gelabert To His Office As Secretary Non-Member Of Audit Committee April 18 (Reuters) - Grifols SA GRLS.MC : BOARD APPROVES RESIGNATION OF TOMÁS DAGÁ GELABERT TO HIS OFFICE AS SECRETARY NON-MEMBER OF THE AUDIT COMMITTEE, WITH IMMEDIATE EFFECT TOMÁS DAGÁ GELABERT CONTINUES AS MEMBER OF THE GRIFOLS' BOARD APPOINTS CURRENT VICE-SECRETARY NON-MEMBER OF BOARD, MS.
G

Spanish stocks - Factors to watch on April 18

Spanish stocks - Factors to watch on April 18 April 18 (Reuters) - The following Spanish stocks may be affected by newspaper reports and other factors on Thursday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy: SANTANDER SAN.MC Spain's Santander will exit the mortgage business in Germany and cut around 500 jobs there by the end of 2026 as part of a process to concentrate on more profitable activities, a spokesperson for the lender told Reuters on Wednesday.
A
B
E
E
G
H
I
S
V
B
S

Spanish stocks - Factors to watch on April 15

Spanish stocks - Factors to watch on April 15 April 15 (Reuters) - The following Spanish stocks may be affected by newspaper reports and other factors on Monday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy: BBVA BBVA.MC The bank's Colombian unit will issue shares worth 220 million euros on the local market to boost growth, it said on Friday.
A
G
S

Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper

RPT-Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper Repeats Sunday's story with no changes to the text MADRID, April 14 (Reuters) - Spanish drug maker Grifols GRLS.MC , battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday.
G

Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper

RPT-Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper Repeats Sunday's story with no changes to the text MADRID, April 14 (Reuters) - Spanish drug maker Grifols GRLS.MC , battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in a newspaper interview published on Sunday.
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.